Vertex Pharmaceuticals Appoints Daniel Brennan to Board as Independent Director

• Vertex Pharmaceuticals appointed Daniel Brennan as an independent director, expanding its board from 10 to 11 members.
• Brennan retired last year as Boston Scientific's executive vice president, chief financial officer, following more than 25 years at the company.
• His healthcare finance experience spans more than 35 years, including responsibility for global finance functions and corporate business development at Boston Scientific.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202610201605BIZWIRE_USPR_____20261019_BW180482) on October 20, 2026, and is solely responsible for the information contained therein.